WHO advises against obesity drugs for children under 10

· Health

The World Health Organization has issued its first guidelines addressing the sharp rise in childhood and adolescent obesity, recommending against GLP-1 drugs for children under 10. For adolescents aged 10 to 19, the WHO said GLP-1 treatments should be used only after a supervised lifestyle program has failed. The guidance lands as drugmakers race to expand the market for blockbuster obesity medicines such as semaglutide and tirzepatide into younger populations. The recommendation could complicate pediatric label expansion plans and shape how payers and regulators approach coverage for minors, even as obesity rates among young people continue to climb worldwide.

Why it matters：A WHO stance against GLP-1 use in young children sets a global reference point that could slow pediatric label expansions and influence how regulators and insurers treat obesity drugs for minors.

Key points

  • WHO recommends against GLP-1 obesity drugs for children under 10.
  • Adolescents aged 10 to 19 should receive them only after a supervised lifestyle program fails.
  • It is the WHO's first set of guidelines addressing rising childhood and adolescent obesity.

Sources (original reporting)

More stories from this day